Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Beats Expectations By $0.08 EPS

Shattuck Labs (NASDAQ:STTK) posted its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08, Briefing.com reports. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%. The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.30 million. Shattuck Labs’s revenue for the quarter was up 2200.0% on a year-over-year basis.

Shattuck Labs Price Performance

STTK traded down $0.32 on Friday, reaching $10.78. The company’s stock had a trading volume of 255,662 shares, compared to its average volume of 357,197. The business’s 50 day moving average is $9.38 and its 200 day moving average is $6.88. Shattuck Labs has a 1 year low of $1.33 and a 1 year high of $11.62. The stock has a market cap of $512.59 million, a price-to-earnings ratio of -5.43 and a beta of 1.98.

Analyst Upgrades and Downgrades

A number of analysts have commented on STTK shares. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Shattuck Labs in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of Shattuck Labs in a research note on Friday.

Insider Transactions at Shattuck Labs

In related news, insider Stephen Stout sold 16,004 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total transaction of $168,522.12. Following the transaction, the insider now directly owns 74,437 shares in the company, valued at $783,821.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.89% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.